BI-2536

Research use only, not for human use.

A potent and selective inhibitor of PLK1 with IC50 of 0.83 nM.

A potent and selective inhibitor of PLK1 with IC50 of 0.83 nM; also weakly inhibits the activities of PLK2 and PLK3 (IC50=3.5 nM and 9.0 nM, respectively), displays >1,000-fold selectivity to a panel of 63 other protein kinases; causes a mitotic arrest and induces apoptosis in human cancer cell lines, inhibits growth of human tumor xenografts in nude mice and induces regression of large tumors with well-tolerated intravenous dose regimens; also inhibits BRD4 with IC50 of 25 nM.Blood Cancer Phase 2 Clinical

BI 2536;BI2536

Cell Cycle/DNA Damage

PLK

Met;PI3Kα;PLK1;PLK2;PLK3

Cancer

Blood cancer

755038-02-9

521.65

C28H39N7O3

>98% (HPLC)

10 mM in DMSO

O=C(NC1CCN(C)CC1)C2=CC=C(NC(N=C3N(C4CCCC4)[C@@H]5CC)=NC=C3N(C)C5=O)C(OC)=C2

Benzamide, 4-[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-

(-20℃)

With Ice Pack

≥ 2 years